# Exosomes Therapy > An independent UK decision guide to exosome therapy in aesthetics and hair, published by Northbank Media. The site covers the treatment category. It names no product and endorses none, has no affiliation with any manufacturer, supplier or distributor, is not a clinic, provides no treatment and gives no medical advice. ## The UK regulatory position, which is the most important fact on this site No exosome product holds a UK marketing authorisation as an injectable medicine for any aesthetic or hair indication. There is no licensed route for injecting an exosome preparation into skin or scalp for cosmetic purposes. The route offered in UK clinics is topical application to skin prepared by microneedling, using products supplied under other classifications. That route has not been licensed as a medicine either. Several frameworks can apply depending on the product and the claims made for it: medicines regulation, the advanced therapy medicinal product framework, human tissue rules, cosmetic product rules and medical device rules. Unlicensed means the independent assessment that produces a licence has not been completed for this use. It does not mean tested and rejected, and it is not reassurance. The current position should be checked with the Medicines and Healthcare products Regulatory Agency. ## What an exosome is A type of extracellular vesicle: a small membrane bound particle released by cells, typically tens to low hundreds of nanometres across, carrying proteins, lipids and nucleic acids, with surface proteins governing which cells it docks with. Commercial preparations vary in source cell, species, isolation method, characterisation standard and dose, and are not comparable with one another. ## The proposed mechanism, and where it is unproven Vesicles carry signals between cells during repair. The proposal is that a concentrated dose delivered into skin or scalp pushes tissue towards a regenerative pattern. Unclosed steps: delivery through an intact barrier is implausible at this particle size, which is why microneedling is used; vesicle survival through storage and application is rarely documented; there is no agreed unit of dose; and clinical effect in humans over months has not been demonstrated at the doses and routes used in aesthetic clinics. ## What the evidence consists of Mostly laboratory studies, then animal studies, with a small human clinical literature. The human studies are characterised by small samples, absent or weak control groups, limited blinding, subjective outcome measures, follow up of weeks to a few months, frequent manufacturer involvement and incomplete product description. Because products described by the same word differ fundamentally, results do not transfer between preparations. The central unanswered question is attribution: the microneedling that delivers the preparation has an effect of its own, and the study design needed to separate the two, needling plus preparation against needling plus placebo, is largely missing. There is no UK registry, no aggregate outcome reporting and no NICE appraisal for cosmetic use. ## Realistic outcomes At best a modest change developing over three to six months, difficult to separate from the effect of the microneedling. For hair, at best a slowing of miniaturisation, assessable only after three to six months because of the hair cycle. The treatment does not lift descended tissue, does not remove established scarring and does not regrow hair from follicles that have been lost rather than miniaturised. ## UK cost, 2026, indicative ranges Full face, one session: £250 to £600. Face, course of three: £700 to £1,500. Face and neck, one session: £350 to £750. Scalp, one session: £300 to £700. Scalp, course of three: £850 to £1,800. Post procedure application at the same visit: £100 to £300. Microneedling alone, for comparison: £150 to £350. London sits at or above the top of each range. These are indicative ranges, not quotations. ## Principal risks From the delivery step: infection, prolonged redness, bruising and swelling, post inflammatory hyperpigmentation particularly in Fitzpatrick types IV to VI appearing two to eight weeks afterwards, granuloma formation and rarely scarring. From the preparation: allergic or hypersensitivity reaction, contamination and batch variability, and unknown long term effects. The preparation risks are unquantified rather than low, because the products are not standardised and no systematic UK adverse event collection exists for them. ## Who should not have it Pregnancy and breastfeeding, active infection or inflammatory acne in the area, broken or inflamed skin, a history of keloid or hypertrophic scarring, bleeding disorders or anticoagulant therapy not discussed with the prescriber, immunosuppression or active autoimmune disease or current cancer treatment without specialist input, recent oral isotretinoin, known allergy to any component, undiagnosed hair loss, and expectations that only surgery could meet. ## Pages - /: the full guide. What exosomes are, the proposed mechanism, the UK regulatory reality, evidence quality, realistic outcomes, cost and contraindications - /hair-loss: exosomes for androgenetic alopecia, compared with platelet rich plasma and the licensed minoxidil and finasteride class - /skin: skin quality and post procedure recovery, and the attribution problem with microneedling - /evidence: a frank review of study quality, sample sizes, control groups, funding and what is missing - /cost: UK 2026 indicative ranges by area and course, what drives the figure, what a low price reflects - /risks-and-regulation: the UK regulatory position in depth, the frameworks that apply, and safety - /vs-alternatives: compared with platelet rich plasma, polynucleotides, microneedling alone and topical actives - /questions-to-ask: a printable twelve question consultation checklist with good and poor answers - /enquire: enquiry form. Details are passed to a registered UK practitioner. No treatment is provided and no medical advice is given by this site - /about: who publishes this and what it refuses to do - /editorial-policy: evidence standards, price presentation, disclosure and correction - /contact: corrections, questions and complaint routes - /exosome-hair-therapy-london-the-complete-guide-to-revolutionary-hair-loss-treatment: what a scalp appointment involves, the UK regulatory position, how the treatment sits against the licensed options for androgenetic alopecia, 2026 price ranges and what to ask before booking - /exosome-stem-cell-therapy-in-london-the-regenerative-frontier-of-aesthetic-medicine: why exosome treatment is not stem cell therapy, what each term describes, where UK regulation draws its lines and how to read a London regenerative offer ## Position No advertising, no affiliate income, no sponsored content, no paid placement, no clinic listings, no before and after galleries and no named products. Enquiries submitted through the enquiry form are passed to a registered UK practitioner, which is disclosed above the form fields. Two articles carry one disclosed editorial link each to an external business, named as an example and never as a recommendation. Neither link was sold, exchanged or paid for, and each of those pages carries a disclosure block saying so. Every other page states that it contains no commercial links. ## External authorities referenced Medicines and Healthcare products Regulatory Agency, General Medical Council, Nursing and Midwifery Council, Joint Council for Cosmetic Practitioners, Save Face, National Institute for Health and Care Excellence, British Association of Dermatologists. Last reviewed 2026-07-31.